Pediatric Pulmonology: Respiratory Care for Children

Pediatric pulmonology is a medical subspecialty focused on diagnosing and managing respiratory diseases in infants, children, and adolescents. The field addresses conditions ranging from congenital lung malformations present at birth to chronic illnesses such as asthma and cystic fibrosis that persist through adolescence and into adulthood. Because children's airways and lungs undergo continuous developmental changes, respiratory disease in this population presents differently than in adults and requires age-specific diagnostic thresholds, dosing strategies, and therapeutic approaches. This page covers the scope of the subspecialty, how pediatric pulmonologists work, the conditions they commonly manage, and the criteria that guide referral decisions.

Definition and scope

Pediatric pulmonology sits at the intersection of general pediatrics and adult pulmonology, applying respiratory medicine principles to patients from the neonatal period through age 18, and in some chronic disease cases through age 21 or beyond during the transition to adult care. The American Board of Pediatrics (ABP) certifies pediatric pulmonologists through a subspecialty examination following completion of a fellowship accredited by the Accreditation Council for Graduate Medical Education (ACGME). Fellowship training requires a minimum of 3 years beyond general pediatrics residency (ACGME Program Requirements for Graduate Medical Education in Pediatric Pulmonology).

The subspecialty's scope is broad. Pediatric pulmonologists manage acute and chronic airway disease, interstitial lung disease, sleep-disordered breathing, neuromuscular respiratory failure, and pulmonary complications of systemic conditions such as sickle cell disease and immunodeficiency. The regulatory context for pulmonary medicine that governs diagnostic coding, device standards, and accreditation applies to pediatric practice under the same federal frameworks — including CMS conditions of participation and FDA device clearances — though pediatric-specific considerations govern dosing and spirometry reference values.

A key boundary distinguishing the subspecialty from general pediatrics is the management of technology-dependent patients: children requiring long-term mechanical ventilation, tracheostomy care, or home oxygen represent a significant share of complex pediatric pulmonology caseloads.

How it works

Evaluation in pediatric pulmonology follows a structured diagnostic process adapted to the patient's developmental stage:

History and symptom characterization — Age of onset, feeding difficulties, growth trajectory, frequency of respiratory infections, and exercise tolerance are all systematically reviewed. In infants, poor weight gain during respiratory illness carries diagnostic weight that differs from adult presentations.
Physical examination — Chest wall deformities such as pectus excavatum, digital clubbing, and accessory muscle use are assessed. Auscultation findings such as wheeze, stridor, and crackles are interpreted against age-specific norms.
Pulmonary function testing (PFT) — Spirometry can be reliably performed in children as young as age 5–6. The Global Lung Function Initiative (GLI) 2012 reference equations, endorsed by the American Thoracic Society (ATS), provide age-, sex-, and ethnicity-adjusted normal ranges for pediatric spirometry (GLI Network, ERS).
Imaging — Chest radiography is the first-line imaging modality; high-resolution CT is used selectively to limit radiation exposure per the ALARA (As Low As Reasonably Achievable) principle outlined by the FDA's Image Gently campaign (FDA, Image Gently).
Specialized testing — Bronchoscopy, bronchial challenge testing, polysomnography, and genetic or sweat chloride testing for cystic fibrosis are ordered based on diagnostic hypotheses developed in earlier steps.
Multidisciplinary coordination — Complex cases, particularly those involving cystic fibrosis or neuromuscular disease, are managed through structured multidisciplinary teams that include respiratory therapists, dietitians, physiotherapists, and social workers, consistent with Cystic Fibrosis Foundation (CFF) care center accreditation standards.

Treatment planning accounts for pediatric-specific pharmacokinetics. Inhaled corticosteroid dosing for asthma, for example, is stratified by low, medium, and high dose tiers using the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 guidelines issued by the National Heart, Lung, and Blood Institute (NHLBI) (NHLBI EPR-3).

Common scenarios

The conditions most frequently managed in pediatric pulmonology practice fall into five broad categories:

Asthma — The most prevalent chronic respiratory disease in children in the United States, affecting approximately 4.7 million children under age 18 as reported in the CDC National Health Interview Survey. Management follows NAEPP step-up/step-down protocols, with controller therapy guided by symptom frequency and spirometric impairment. For a detailed review of the condition, see the asthma reference page.
Cystic fibrosis (CF) — A genetic disease caused by mutations in the CFTR gene, affecting mucus clearance in the lungs, pancreas, and other organs. The CFF Patient Registry tracks outcomes across more than 300 accredited CF care programs in the United States. CFTR modulator therapies (e.g., elexacaftor-tezacaftor-ivacaftor) are now approved for patients as young as age 2 for eligible mutations (FDA drug approvals database).
Recurrent pneumonia and bronchiectasis — Children with 2 or more radiographically confirmed pneumonia episodes in a single year, or pneumonia in the same lobe on 2 or more occasions, prompt evaluation for underlying structural, immunologic, or aspiration-related causes. Bronchiectasis is a recognized end-organ outcome of inadequately managed recurrent infection.
Sleep-disordered breathing — Obstructive sleep apnea in children differs from the adult form; adenotonsillar hypertrophy is the dominant etiology in the 2–8 age range. The American Academy of Sleep Medicine (AASM) defines pediatric obstructive sleep apnea as an apnea-hypopnea index (AHI) of greater than 1 event per hour, a threshold substantially lower than the adult criterion of 5 events per hour (AASM International Classification of Sleep Disorders, 3rd ed.).
Neuromuscular respiratory disease — Conditions including spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and congenital myopathies impair respiratory muscle strength, leading to progressive hypoventilation. Surveillance spirometry and nocturnal oximetry guide the timing of noninvasive ventilation initiation.

Decision boundaries

Distinguishing when a pediatric patient should be managed by a general pediatrician versus referred to a pediatric pulmonologist involves several threshold criteria. The pulmonary authority index of respiratory subspecialties provides broader context for how these decision points map across the field.

Refer to pediatric pulmonology when:

Asthma is uncontrolled despite step 3 therapy (medium-dose inhaled corticosteroid plus a second controller agent) per NAEPP EPR-3 criteria.
A child has experienced 2 or more hospitalizations for respiratory illness in a 12-month period.
Spirometry shows an FEV1 below 80% predicted and is not fully reversible with bronchodilator.
Suspected cystic fibrosis requires sweat chloride testing and genetic analysis.
Polysomnography is indicated for sleep-disordered breathing evaluation.
Recurrent pneumonia raises concern for an underlying structural or immune defect.
A neonate is discharged from the NICU on supplemental oxygen or respiratory support equipment.

Pediatric pulmonology versus adult pulmonology — The primary contrast lies not in disease category but in physiologic context. Pediatric lungs continue alveolar development until approximately age 8, and airways grow proportionally with somatic growth through adolescence. This means that an obstruction or airway lesion of identical absolute size carries a proportionally greater functional impact in a 3-year-old than in an adult. Reference ranges for all pulmonary function measures must use age- and height-adjusted pediatric equations, not adult norms. Transition to adult pulmonary care is a structured process, ideally beginning at age 16–17, and follows guidance from professional bodies including the Society for Adolescent Health and Medicine (SAHM).

For patients managing chronic cough, wheezing and chest tightness, or recurrent respiratory infections, these symptom-specific reference pages provide condition-level detail that complements the subspecialty overview provided here.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)